GlassScriptPhysician profile
Basel Alhaddad
NPI 1487741120
$1,637.74
in general payments reported to CMS, 2019-2025
15 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $124 · 2021: $125 · 2022: $241 · 2023: $139 · 2024: $412 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.75 |
| Education | $135.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $623.69 | 2019-2025 | Jardiance |
| Janssen Scientific Affairs, LLC | $193.58 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Insmed, INC. | $115.89 | 2022 | |
| Abiomed | $101.64 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $94.99 | 2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $69.05 | 2024-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $65.44 | 2025 | |
| Csl Behring | $52.63 | 2023 | Kcentra |
| Janssen Pharmaceuticals, INC | $49.04 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.98 | 2019 | |
| Angiodynamics, INC. | $29.23 | 2024-2025 | Auryon Laser System 100-120 Vac |
| E.R. Squibb & Sons, L.L.C. | $28.76 | 2024 | Eliquis |
| Alkermes, INC. | $23.68 | 2024 | Vivitrol |
| Convatec INC. | $20.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Alhaddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.